{"filings":[{"id":1922717,"accession_number":"0001171843-26-004977","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2026-07-29T11:20:33+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q2 revenue $32.6M (+16% YoY); raises FY 2026 guidance, adj. EBITDA margin 13-17%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $32.6M, up 16% YoY; Commercial Channel record $13.9M (+17%); OEM $18.7M (+14%).","Gross margin 65%; net income $3.3M ($0.24 diluted EPS); adjusted EBITDA $7.1M (22% margin).","Raising FY 2026 guidance: total revenue growth 5-10% (prev 1-9%); adj. EBITDA margin 13-17% (prev 5-10%).","Revised 2027 Commercial revenue growth 5-15% (prev 10-20%); total company flat to 5% growth.","International revenue record $12.6M (+22% YoY); Integrity units up 39% YTD; Hyalofast/Cingal progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1639199,"accession_number":"0001171843-26-004635","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2026-07-14T21:00:16+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Anika Therapeutics enters Fifth Amendment to credit agreement, $50M revolver due 2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$50M senior revolving credit facility with Bank of America, maturity July 10, 2031.","Option to increase commitments by up to $50M (total $100M) subject to lender approval.","Interest rate: SOFR plus 0.25%-1.25% based on leverage ratio; commitment fee 0.20%-0.30% on unused portion.","Financial covenants include max leverage and interest coverage ratios; first-priority lien on substantially all assets.","Amendment reduces revolving facility from prior amount to $50M; certain lenders exit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1222087,"accession_number":"0001171843-26-004253","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2026-06-23T20:05:18+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Anika shareholders approve share reserve increases for equity plans at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2017 Omnibus Incentive Plan, increasing reserved shares from 5,760,000 to 6,110,000 (350,000 share increase).","Stockholders approved amendment to 2021 Employee Stock Purchase Plan, increasing reserved shares from 200,000 to 400,000 (200,000 share increase).","Directors Gary P. Fischetti, John B. Henneman III, and Stephen D. Griffin elected as Class III directors until 2029 annual meeting.","Ratification of Deloitte & Touche as independent auditor for FY2026 passed: 11,136,590 for, 24,966 against, 34,111 abstain.","Advisory say-on-pay vote passed: 8,268,676 for, 1,093,946 against, 31,179 abstain; 1,801,866 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99588,"accession_number":"0001171843-26-002799","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Anika Q1 revenue up 13% to $29.6M; adjusted EBITDA improves to $4.3M; directors resign","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $29.6M (+13% YoY); Commercial Channel +12%, OEM +14%.","Gross margin 64.2% vs 56.1% YoY on operational execution and favorable mix.","GAAP loss from continuing ops $5.1M ($0.37 diluted); adjusted net income $3.8M ($0.27 diluted).","Adjusted EBITDA $4.3M vs $0.1M prior year; FY2026 guidance reaffirmed (revenue $114-122.5M).","Board members Jellison and Larsen resign effective 2026 annual meeting; share repurchase $15M completed at avg $10.76/share."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":29612000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115681,"accession_number":"0001193125-26-073401","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Anika Q4 rev flat, FY rev -6%; guides 2026 rev $114-122.5M; GC Colleran to depart May 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $30.6M flat YoY; GAAP EPS $0.13, adjusted EPS $0.31; gross margin 63%.","FY25 revenue $112.8M (-6%); GAAP loss ($0.70)/share; adjusted EPS $0.11; adjusted EBITDA $5.3M.","Commercial Channel rev +22% Q4, +15% FY; OEM -12% Q4, -17% FY.","FY26 guidance: rev $114-122.5M (1-9% growth); adj. EBITDA margin 5-10%; $15M buyback continuing.","EVP, General Counsel David Colleran to depart May 1, 2026 under transition agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":112819000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115680,"accession_number":"0001193125-26-007655","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Anika Therapeutics appoints Steve Griffin CEO effective Feb 1, 2026; Cheryl Blanchard becomes Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Griffin, current CFO & COO, promoted to President and CEO effective Feb 1, 2026.","Cheryl Blanchard transitions from CEO to Executive Chair for 12 months, then Special Advisor.","Reaffirmed FY2025 guidance: Commercial Channel $47-49.5M (+12-18% YoY), OEM $62-65M (-16-20% YoY).","Director Susan Vogt resigns effective Feb 1, 2026; no disagreements with the Company.","Griffin receives $690k base salary, 75% target bonus, and $2.45M equity grant vesting over three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132111,"accession_number":"0001171843-25-007003","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Anika Q3 revenue down 6% to $27.8M; files final Hyalofast PMA with mixed Phase III data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 continuing ops rev $27.8M (-6% YoY); loss per share ($0.22); adj EPS $0.04; adj EBITDA $0.9M.","Commercial Channel rev up 22% YoY; Integrity procedures on track to double in 2025; J&J extends Monovisc license to 2031.","Commencing $15M share repurchase via 10b5-1 plan expected to complete by June 2026.","Filed final Hyalofast PMA module; Phase III trial missed primary endpoints but showed significant secondary endpoint benefits.","Hyalofast used in >35K patients globally; Breakthrough Device Designation; post-hoc analyses showed statistical significance in KOOS Pain."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":82204000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148681,"accession_number":"0001171843-25-004810","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Therapeutics Q2 2025 revenue down 8%; Hyalofast trial misses co-primary endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $28.2M, down 8% YoY; Commercial Channel flat, OEM Channel down 13%","Regenerative Solutions revenue rose 41% driven by Integrity implant outperformance (full-year 2024 surpassed in H1 2025)","Hyalofast Phase III trial missed co-primary endpoints but showed statistically significant improvements in secondary endpoints; final PMA module on track for H2 2025","Company reaffirms 2025 revenue/EBITDA guidance but revises long-term outlook for Hyalofast launch potential delay to 2027","Operating expenses down 17% YoY; production yield issues resolved in June 2025 with no patient impact"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":54387000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148680,"accession_number":"0001171843-25-004809","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anika's Hyalofast Phase III misses co-primary endpoints; plans PMA filing by end of 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Hyalofast missed pre-specified co-primary endpoints (percent change in KOOS Pain and IKDC function vs microfracture) on statistical significance.","Statistically significant improvements on secondary endpoints: KOOS Sports & Recreation, Quality of Life, and Total KOOS.","Safety profile comparable to microfracture; company plans to file final PMA module in H2 2025.","Over 35,000 patients treated outside U.S. since 2009; independent studies support safety and efficacy.","Study impacted by higher dropout in microfracture arm and COVID-related missed visits, reducing evaluable sample size."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167558,"accession_number":"0001171843-25-004062","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Anika Therapeutics stockholders approve 475,000-share increase in incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share reserve under 2017 Omnibus Incentive Plan raised from 5,285,000 to 5,760,000.","All three Class II director nominees elected: Blanchard, Capper, Larsen.","Advisory say-on-pay vote passed with 8,374,076 for vs 2,529,081 against.","Deloitte & Touche ratified as independent auditor for fiscal 2025.","Annual meeting had 86.13% of voting power present; no opposition to board's solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167557,"accession_number":"0001171843-25-003005","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q1 revenue down 10% to $26.2M; lowers FY2025 Adj. EBITDA guidance to -3% to 3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $26.2M, down 10% YoY; OEM channel down 23% to $14.9M, Commercial channel up 18% to $11.3M.","Adjusted net loss from continuing ops $0.9M ($0.06/share); Adjusted EBITDA $0.1M; cash $53.4M, no debt.","Updated FY2025 guidance: OEM revenue $62-65M (down 16-20%); Adj. EBITDA -3% to 3% (prev 8-10%).","Integrity procedures on pace to more than double in 2025; over 300 surgeries in Q1; Regenerative Solutions portfolio up 33% YoY.","Key regulatory milestones: Hyalofast second PMA module filed, MDR approved; Cingal NDA path cleared with FDA feedback."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":26168000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167556,"accession_number":"0001171843-25-002148","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Anika Therapeutics announces departure of COO Anne Nunes, eliminates position","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anne Nunes departs as Chief Operations Officer effective April 25, 2025.","She receives severance per her Executive Retention Agreement (filed as Exhibit 10.14 to 10-K).","Stephen Griffin (EVP, CFO, COO) assumes manufacturing and operations functions.","Company eliminates Chief Operations Officer role; no replacement planned.","Griffin's annual compensation remains unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184847,"accession_number":"0001171843-25-001437","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Therapeutics reports Q4 2024 revenue $30.6M, full year $119.9M; guides 2025 adj EBITDA margin 8-10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue from continuing ops $30.6M (+1% YoY); full-year revenue $119.9M (-1% YoY).","Commercial Channel revenue up 25% in Q4 ($10.9M) and 17% for full year ($42.1M).","Net loss from continuing ops: Q4 ($2.5M), ($0.17)/share; FY ($8.8M), ($0.60)/share.","FY 2025 guidance: Commercial Channel $47-49.5M (+12-18%), OEM Channel $64-68.5M (-12-18%).","Sale of Parcus Medical completed Mar 7; $5.6M in stock repurchased in Q4, $15M plan completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184846,"accession_number":"0001171843-25-001388","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Anika completes sale of Parcus Medical for $4.5M cash, sharpens focus on OA pain management","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale closed March 7, 2025 to Medacta Group SA (Medacta Americas Manufacturing).","Cash consideration of $4.5M at closing, subject to customary post-closing adjustments.","Divestiture part of previously announced strategic review; company to focus on hyaluronic acid and regenerative solutions.","Parcus Medical was a wholly owned subsidiary; Anika received total cash consideration at closing.","Goodwin Procter served as legal counsel; Piper Sandler as exclusive financial advisor to Anika."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201439,"accession_number":"0001171843-24-005923","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q3 rev $38.8M (-7% YoY), net loss $29.9M; restructures, sells Arthrosurface, plans Parcus divestiture","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $38.8M (-7% YoY), net loss $29.9M ($2.03/sh); adj net loss $3.8M ($0.25/sh).","Integrity Implant System grew 40%+ sequentially, >500 surgeries since launch, Regenerative Solutions up 17%.","Exiting Arthrosurface (sold) and Parcus Medical (divestiture planned) to focus on HA technology and Commercial Channel.","Updated 2024 guidance: Commercial Channel +14% to +19%, OEM -8% to -10%, Adj EBITDA $16-18M; restructuring charges $3-5M cash, $27-29M non-cash.","First Hyalofast PMA module filed Oct 28; Cingal NDA path progress including acquisition of Aristospan NDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":121197000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201438,"accession_number":"0001171843-24-005922","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Anika Therapeutics completes sale of Arthrosurface for $10M; plans to divest Parcus Medical","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold Arthrosurface to Phoenix Brio for $7M note plus up to $3M contingent consideration based on sales performance.","Announced intention to sell Parcus Medical sports medicine business as part of strategic review.","Focus shifts to core hyaluronic acid (HA) products and Regenerative Solutions, targeting $4B global market.","Piper Sandler serving as exclusive financial advisor for both the Arthrosurface sale and potential Parcus divestiture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217443,"accession_number":"0001171843-24-004607","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q2 revenue $41.9M (-5% YoY); net loss $0.1M; launches Integrity Implant System","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $41.9M, down 5% YoY; OA Pain Mgmt $26.7M (-9%), Joint Preservation $13.5M (+7%).","Net loss $0.1M ($0.01/sh); adjusted net income $2.5M ($0.17/sh); adjusted EBITDA $6.3M.","Full market release of Integrity Implant System (HA scaffold) in July; >300 cases by >60 surgeons.","Guidance: FY2024 revenue $168-$173M (1-4% growth); adjusted EBITDA towards lower end of $25-$30M.","New $40M share repurchase program; $15M under 10b5-1 plan initiated May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":82444000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217442,"accession_number":"0001171843-24-003900","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Anika Therapeutics stockholders elect directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Sheryl L. Conley, William R. Jellison, Stephen O. Richard as Class I directors (2027 term).","Ratified Deloitte & Touche LLP as independent auditor: 12,337,376 for, 43,654 against.","Say-on-pay proposal passed on a non-binding advisory basis: 11,020,273 for, 129,717 against.","Annual meeting turnout: 12,387,064 shares voted, representing 83.37% of entitled voting power.","No contested solicitations; all board proposals carried with substantial majority support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237307,"accession_number":"0001171843-24-003136","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Anika Therapeutics adds two directors, announces $40M buyback under Caligan deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Joseph Capper (MIMEDX CEO) and William Jellison (former Stryker CFO) to Board; board expands to 10 then reduces to 9 after 2024 annual meeting.","Authorized $40M share repurchase program: $15M via 10b5-1 by June 2025, remainder open market through June 2026, replacing April 2023 program.","Caligan agrees to standstill, voting commitments, and other provisions under cooperation agreement.","Reaffirmed 2024 adjusted EBITDA guidance of $25-30M, up >75% YoY at midpoint.","New directors join Capital Allocation Committee; no prior relationships or transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237306,"accession_number":"0001171843-24-002673","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anika Therapeutics appoints Stephen Griffin as CFO replacing Michael Levitz effective June 3, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Griffin appointed EVP, CFO and Treasurer of Anika Therapeutics, effective June 3, 2024.","Griffin receives $500K base salary, 60% target bonus, and $2M equity grant split between RSUs and stock options.","Michael Levitz resigned as CFO on May 2; will stay through Dec 31, 2024 for transition, receiving $100K one-time payment.","Levitz's separation includes continued salary through year-end and a general release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237305,"accession_number":"0001171843-24-002672","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Therapeutics Q1 revenue up 7% to $40.5M; narrows net loss; reaffirms FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $40.5M (+7% YoY); net loss narrowed to $4.5M from $10.4M; adjusted net income $1.2M ($0.09/dil share).","Adjusted EBITDA improved to $2.5M from ($1.2M) in Q1 2023; FY2024 adj EBITDA guidance $25-30M (midpoint up >75%).","Cost reduction initiatives completed, achieving $10M annualized savings; severance costs $0.8M in Q1.","Business highlights: extended Canadian distribution deal through 2030; >10,000 X-Twist anchors sold; Integrity Implant >200 cases."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":40523000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254848,"accession_number":"0001171843-24-001322","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q4 revenue $43.0M (+8%), net loss incl. $62.2M impairment; guides FY2024 adj. EBITDA $25-30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $43.0M (+8% YoY); net loss ($63.0M) or ($4.30)/share due to $62.2M non-cash impairment on Arthrosurface/Parcus intangibles.","FY2023 revenue $166.7M (+7% YoY); OA Pain Management record $101.9M (+11%).","Announces ~9% workforce reduction expected to save ~$10 million annually in 2024.","FY2024 guidance: revenue $168-173M (+1-4%), adj. EBITDA $25-30M (margin at least 15%), up >75% at midpoint.","Engaged Piper Sandler for strategic review, evaluating alternatives including potential sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254847,"accession_number":"0001171843-24-000972","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Jeffery S. Thompson to retire; John B. Henneman appointed Board Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffery S. Thompson will retire from Anika's Board at the 2024 Annual Meeting after 13 years.","John B. Henneman, III, an independent director since 2020, appointed Board Chair effective immediately.","Thompson's retirement not due to any disagreement with the Company's operations, policies, or practices.","Board will have seven directors after Thompson's departure; two Class I directors to be elected at Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272330,"accession_number":"0001171843-23-006678","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q3 revenue $41.5M (+3% YoY); raises FY2023 guidance to $164-166M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $41.5M (+3% YoY); Joint Preservation & Restoration up 14% to $13.5M, OA Pain Mgmt up 2% to $24.9M.","Net loss ($6.6M), ($0.45)/share; adjusted net income $0.00/diluted share; includes $4.2M software charge.","Adjusted EBITDA $4.7M vs $4.1M; cash from ops $6.5M, cash $70.7M.","Raised FY2023 revenue guidance to $164-166M (from $159.5-163M), implying 5-6% growth.","FDA cleared Integrity Implant System (rotator cuff patch) and X-Twist biocomposite; launches Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":123691000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289167,"accession_number":"0001171843-23-005813","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anika Therapeutics files investor presentation with pipeline updates; no financial details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation for Sidoti Small Cap Conference dated September 21, 2023, furnished as Exhibit 99.1.","Slide deck covers corporate updates, product portfolio, and pipeline, but attached exhibit contains only title slide.","No specific revenue, profit, guidance, or clinical data disclosed in the filing or exhibit provided.","Company refers to its website for full presentation; this filing is procedural under Item 7.01."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289166,"accession_number":"0001171843-23-005107","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q2 revenue rises 12% to $44.3M; raises FY2023 guidance floor to $159.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $44.3M (+12% YoY); net loss ($0.19)/share; adjusted EPS $0.06 vs ($0.12) prior year.","OA Pain Mgmt rev +22% to $29.3M; Joint Preservation & Restoration +5% to $12.7M.","FY2023 rev guidance raised: $159.5M-$163M (was $158M-$163M), representing 2-4% growth.","Hyalofast Phase III fully enrolled; PMA submission begins 2024; Cingal ongoing FDA discussions after Type-C meeting.","RevoMotion reverse shoulder full market launch accelerated to Sept 2023; Integrity rotator cuff patch 2024 launch on track."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":82226000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309931,"accession_number":"0001171843-23-004058","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Anika appoints Anne Nunes as SVP, COO; shareholders approve 435K-share plan increase","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anne Nunes appointed SVP, Chief Operations Officer effective June 19, 2023; base salary $440,000, target bonus 45%.","Stockholders approved amendment increasing 2017 Plan share reserve by 435,000 to 5,285,000 shares.","Gary Fischetti, John Henneman, and Susan Vogt elected Class III directors until 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309930,"accession_number":"0001171843-23-003096","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q1 revenue up 3% to $37.9M but net loss widens to $10.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["OA Pain Mgmt rev $22.6M (+8% YoY); Joint Preservation & Restoration rev $13.5M (+11% YoY).","Net loss ($10.4M) or ($0.71)/share; adjusted net loss ($5.3M) or ($0.36)/share.","Adj EBITDA ($1.2M) vs +$2.6M in Q1 2022; gross margin 60% (adj 64%).","FY 2023 rev guidance reaffirmed at $158-163M; $20M share buyback authorized.","Post-quarter: settled Parcus arbitration, cooperation with Caligan, added director Fischetti."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":37924000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309929,"accession_number":"0001193125-23-124376","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anika Therapeutics pays $3.25M to settle Parcus Medical earnout arbitration","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Paid $3.25M one-time settlement to Philip Mundy, Parcus Medical unitholder rep, to resolve earnout arbitration.","Parties mutually released all claims, including unknown claims, arising from the 2020 Merger Agreement.","Company denies any fault or liability; settlement entered to avoid burden and expense of further arbitration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309928,"accession_number":"0001193125-23-100714","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Anika enters cooperation with Caligan, appoints director, authorizes $20M buyback","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Gary Fischetti as Class III director; Board expands to eight members.","Authorized $20M share repurchase: $5M accelerated, $5M open market, $10M subject to positive cash flow.","Formed Capital Allocation Committee with Fischetti, Henneman, and Thompson.","Caligan agreed to standstill and voting commitments supporting Board's 2023 slate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328626,"accession_number":"0001171843-23-001426","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q4 revenue up 11% to $39.6M; net loss $4.9M; FY2023 guidance $158-163M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $39.6M (+11% YoY); OA Pain Mgmt $23.7M (+20%), Joint Preservation $14.3M (+8%).","Q4 net loss ($4.9M) or ($0.34) per share; adjusted net loss ($3.0M) or ($0.21) per share.","Full year 2022 revenue $156.2M (+6%); net loss ($14.9M) vs net income $4.1M in 2021.","FY2023 revenue guidance $158-163M (1-4% growth); OA Pain Mgmt $93.5-96M, Joint Preservation $55.5-58M.","Hyalofast Phase III trial 199/200 enrolled; Cingal engaging FDA; RevoMotion limited release initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346299,"accession_number":"0001171843-22-007233","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q3 revenue $40.3M (+2% YoY); net loss ($4.2M); Cingal Phase III hits endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $40.3M (+2% YoY); OA Pain Mgmt $25.7M (-2%), Joint Preservation $11.8M (+6%), Non-Ortho $2.8M (+27%).","Net loss ($4.2M) vs net income $0.6M prior year; adjusted net loss ($0.7M); adjusted EBITDA $4.1M vs $5.7M.","Cingal Phase III (Cingal 19-01) achieved primary endpoint — superiority over steroid alone at 26 weeks; FDA meeting planned.","Hyalofast pivotal Phase III 96% enrolled (193 patients); full enrollment expected early 2023; PMA filing on track for 2025.","FY2022 guidance: overall revenue toward upper end of low to mid single-digit growth; OA Pain Mgmt now expected up mid to upper single-digit %."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":116614000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346298,"accession_number":"0001171843-22-006969","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anika's Cingal succeeds in Phase III 19-01, beats steroid alone at 26 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cingal met primary endpoint in U.S. Phase III study 19-01: superior to TH steroid at 26 weeks (p=0.0406).","Across three Phase III studies (n=741), Cingal showed mean 71% pain improvement and 91% responder rate at 26 weeks.","Anika to meet FDA in coming months to discuss next steps for U.S. regulatory approval of Cingal.","FDA may require a single full factorial pivotal study before NDA submission, as per prior advice.","Cingal already commercialized in over 35 countries; Anika exploring U.S. and Asian commercial partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362685,"accession_number":"0001171843-22-005312","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q2 rev $39.7M (+4%); net loss ($2.8M) vs prior profit $6.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $39.7M (+4% YoY); OA Pain Mgmt $25.7M (+6%), Joint Preservation $12.1M (+2%).","Net loss ($2.8M) or ($0.20)/share vs prior net income $6.5M ($0.45); adjusted net loss ($1.6M) or ($0.12)/share.","Adjusted EBITDA $4.4M vs $6.1M; cash $91.4M, no debt.","X-Twist Fixation System FDA 510(k) clearance received; limited market release on schedule for 2H 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":76350000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382267,"accession_number":"0001171843-22-004296","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Anika shareholders approve 250,000-share increase in 2017 incentive plan, reelect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment increasing shares under 2017 Omnibus Plan from 4.6M to 4.85M; 10.1M in favor, 2.25M against.","Cheryl R. Blanchard (Ph.D.) reelected as Class II director with 11.36M votes for, 1.11M against; Glenn R. Larsen (Ph.D.) with 11.98M for, 0.32M against.","Ratification of Deloitte & Touche as auditor passed with 13.13M for, 0.08M against, 15.3K abstain; advisory say-on-pay passed with 12.15M for.","Meeting turnout: 13.22M shares present (91.07% of voting power)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382266,"accession_number":"0001171843-22-003332","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q1 revenue $36.7M (+7% YoY); net loss ($2.9M) vs. income; reaffirms FY22 growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["OA Pain Management revenue $22.7M (+18% YoY); Joint Preservation & Restoration $12.1M (-1%).","Net loss ($2.9M), ($0.20) per share vs. net income $2.8M ($0.20 diluted) in prior year.","Adjusted net loss ($1.6M), adjusted gross margin 64% (down YoY) due to supply chain/challenges.","Cash $90.3M; FY2022 revenue expected toward upper end of low-to-mid single digit growth.","Appointed Rob Delp as VP U.S. Sales; he previously led Americas for Zimmer Biomet."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":36693000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400203,"accession_number":"0001171843-22-001706","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika reports Q4 2021 revenue $35.8M (+10% YoY); full year $147.8M (+13%); guides FY2022 low-to-mid single digit growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $35.8M (+10% YoY); net loss $5.8M ($0.40 diluted) vs $15.7M loss prior year.","Full-year 2021 revenue $147.8M (+13% YoY); net income $4.1M ($0.28 diluted) vs $24.0M loss in 2020.","Adjusted net loss Q4 $3.2M ($0.23 diluted) vs adjusted net income $1.7M prior year; adjusted EBITDA loss $0.2M vs $4.0M.","FY2022 guidance: revenue growth low-to-mid single digit; Joint Preservation mid-single to low-double digit, OA Pain low-single digit.","Cash balance $94.4M; operating cash flow $9.0M for full year; completed enrollment of Cingal pilot trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419177,"accession_number":"0001171843-21-007914","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Anika Therapeutics enters $75M senior revolving credit facility maturing 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Third Amendment to Credit Agreement increases revolving line to $75M, expandable to $150M.","Maturity date extended to November 12, 2026; interest at BSBY + 0.25%-1.00%.","Amended agreement governs leverage and interest coverage covenants; first-priority lien on assets.","Bank of America serves as administrative agent; new lenders join the facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419176,"accession_number":"0001171843-21-007565","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q3 revenue up 25% to $39.5M, net income $0.6M; cuts FY2021 revenue growth outlook to 9-11% from 11-14%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $39.5M (+25% YoY); Joint Pain Management up 42% to $26.2M.","Net income $0.6M ($0.04 diluted) vs net loss $6.4M a year ago; adjusted net income $0.8M ($0.05 diluted).","Adjusted EBITDA $5.8M vs $4.9M; operating cash flow $2.1M; cash $91.0M.","FY2021 revenue growth guidance revised to 9-11% (previously 11-14%) due to COVID Delta variant headwinds.","Launched WristMotion Total Wrist Arthroplasty; received 510(k) clearance for Tactoset hardware augmentation."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":111973000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419175,"accession_number":"0001171843-21-007366","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2021-11-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Anika Therapeutics appoints Sheryl Conley to Board of Directors; adds orthopedic industry expertise","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Sheryl Conley as independent director effective Oct 28, 2021; board expands from seven to eight members.","Ms. Conley brings over 35 years of orthopedic experience, including 25 years at Zimmer as Group President and CMO.","She will serve on the Audit Committee and received 8,179 restricted stock units vesting over three years.","Currently President of AcceLINX and board member at Neuronetics (STIM) and Surgalign (SRGA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436717,"accession_number":"0001171843-21-005577","cik":898437,"company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anika Q2 revenue $38.1M (+24% YoY); raises FY revenue growth outlook to 11-14%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $6.5M ($0.45 diluted EPS) vs net loss $7.7M in Q2 2020.","Adjusted net income $1.4M ($0.09 diluted EPS); adjusted EBITDA $6.1M.","Joint Preservation and Restoration revenue up 79% to $11.9M; segment now 31% of total.","Company raises FY 2021 revenue growth guidance to 11-14% from prior 10-13%.","First surgical case with WristMotion Total Wrist implant; 510(k) clearance for reverse shoulder system."],"consensus_eps_estimate":null,"consensus_eps_actual":0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":72437000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":197056296.05507052,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}